文献

J-GLOBAL ID：201802211897978100   整理番号：18A1691340

NUDT15コドン139は炎症性腸疾患の日本人患者におけるチオプリン誘発重度有害事象を予測する最高の薬理遺伝学的マーカーである:多施設研究

NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study

著者 (40件)： KAKUTA Yoichi (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  KAWAI Yosuke (Tohoku Univ., Sendai, JPN) ,  KAWAI Yosuke (Univ. Tokyo, Tokyo, JPN) ,  OKAMOTO Daisuke (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  TAKAGAWA Tetsuya (Hyogo Coll. of Medicine, Nishinomiya, JPN) ,  IKEYA Kentaro (Hamamatsu South Hospital, Hamamatsu, JPN) ,  SAKURABA Hirotake (Hirosaki Univ. Graduate School of Medicine, Hirosaki, JPN) ,  NISHIDA Atsushi (Shiga Univ. Medical Sci., Otsu, JPN) ,  NAKAGAWA Shoko (Aichi Medical Univ. School of Medicine, Nagakute, JPN) ,  MIURA Miki (Kyorin Univ. School of Medicine, Mitaka, JPN) ,  TOYONAGA Takahiko (Kitasato Univ. Kitasato Inst. Hospital, Tokyo, JPN) ,  ONODERA Kei (Sapporo Medical Univ. School of Medicine, Sapporo, JPN) ,  SHINOZAKI Masaru (Univ. Tokyo, Tokyo, JPN) ,  ISHIGURO Yoh (Hirosaki National Hospital, Hirosaki, JPN) ,  MIZUNO Shinta (Keio Univ. School of Medicine, Tokyo, JPN) ,  TAKAHARA Masahiro (Okayama Univ. Graduate School of Medicine, Dentistry, and Pharmaceutical Sci., Okayama, JPN) ,  YANAI Shunichi (Iwate Medical Univ., Morioka, JPN) ,  HOKARI Ryota (National Defense Medical Coll., Tokorozawa, JPN) ,  NAKAGAWA Tomoo (Chiba Univ., Chiba, JPN) ,  ARAKI Hiroshi (Gifu Univ. Hospital, Gifu, JPN) ,  MOTOYA Satoshi (Sapporo-Kosei General Hospital, Sapporo, JPN) ,  NAITO Takeo (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  MOROI Rintaro (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  SHIGA Hisashi (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  ENDO Katsuya (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  KOBAYASHI Taku (Kitasato Univ. Kitasato Inst. Hospital, Tokyo, JPN) ,  NAGANUMA Makoto (Keio Univ. School of Medicine, Tokyo, JPN) ,  HIRAOKA Sakiko (Okayama Univ. Graduate School of Medicine, Dentistry, and Pharmaceutical Sci., Okayama, JPN) ,  MATSUMOTO Takayuki (Iwate Medical Univ., Morioka, JPN) ,  NAKAMURA Shiro (Hyogo Coll. of Medicine, Nishinomiya, JPN) ,  NAKASE Hiroshi (Sapporo Medical Univ. School of Medicine, Sapporo, JPN) ,  HISAMATSU Tadakazu (Kyorin Univ. School of Medicine, Mitaka, JPN) ,  SASAKI Makoto (Aichi Medical Univ. School of Medicine, Nagakute, JPN) ,  HANAI Hiroyuki (Hamamatsu South Hospital, Hamamatsu, JPN) ,  ANDOH Akira (Shiga Univ. Medical Sci., Otsu, JPN) ,  NAGASAKI Masao (Tohoku Univ., Sendai, JPN) ,  KINOUCHI Yoshitaka (Tohoku Univ., Sendai, JPN) ,  SHIMOSEGAWA Tooru (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  MASAMUNE Atsushi (Tohoku Univ. Graduate School of Medicine, Sendai, JPN) ,  SUZUKI Yasuo (Toho Univ. Sakura Medical Center, Sakura, JPN)
資料名： Journal of Gastroenterology  (Journal of Gastroenterology)
巻： 53  号： 9  ページ： 1065-1078  発行年： 2018年 
JST資料番号： Z0748A  ISSN： 0944-1174  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： ・炎症性腸疾患(IBD)患者におけるチオプリン誘発有害事象(...

シソーラス用語： ヒト ,...
準シソーラス用語： ROC解析 ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1691340&from=J-GLOBAL&jstjournalNo=Z0748A") }}

分類 (1件)： 消化器疾患の薬物療法  (GH05020G)

物質索引 (3件)： 6-メルカプトプリン ,  アザチオプリン ,  サラゾスルファピリジン

引用文献 (31件)：

• Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53(3):305-53.
• Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38(8):740-6.
• Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):630-42.
• Panaccione R, Ghosh S, Middleton S, Marquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392-400.
• Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383-95.

タイトルに関連する用語 (13件)： NUDT15 ,  コドン ,  炎症性腸疾患 ,  日本人 ,  患者 ,  チオプリン ,  誘発 ,  重度有害事象 ,  予測 ,  薬理遺伝学 ,  マーカー ,  施設 ,  研究